| pubmed-article:10438370 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10438370 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:10438370 | lifeskim:mentions | umls-concept:C0023290 | lld:lifeskim |
| pubmed-article:10438370 | lifeskim:mentions | umls-concept:C0021745 | lld:lifeskim |
| pubmed-article:10438370 | lifeskim:mentions | umls-concept:C0013089 | lld:lifeskim |
| pubmed-article:10438370 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:10438370 | lifeskim:mentions | umls-concept:C1517004 | lld:lifeskim |
| pubmed-article:10438370 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:10438370 | pubmed:dateCreated | 1999-9-23 | lld:pubmed |
| pubmed-article:10438370 | pubmed:abstractText | Active targeting of doxorubicin to macrophages was studied by incorporating it in mannose-coated liposomes by use of visceral leishmaniasis in BALB/c mice as the model macrophage disease. Mannosylated liposomal doxorubicin was more effective than liposomal doxorubicin or free doxorubicin. Because leishmaniasis is accompanied by immunosuppression, immunostimulation by interferon (IFN)-gamma was evaluated to act synergistically with mannosylated liposomal doxorubicin therapy. Combination chemotherapy with a suboptimal dose of IFN-gamma resulted in possibly complete elimination of spleen parasite burden. Analysis of mRNA levels of infected spleen cells suggested that targeted drug treatment together with IFN-gamma, in addition to greatly reducing parasite numbers, resulted in reduced levels of interleukin (IL)-4 but increased levels of IL-12 and inducible nitric oxide synthase. Such combination chemotherapy may provide a promising alternative for the cure of leishmaniasis, with a plausible conversion of antiparasitic T cell response from a Th2 to Th1 pattern indicative of long-term resistance. | lld:pubmed |
| pubmed-article:10438370 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10438370 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10438370 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:10438370 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10438370 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10438370 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10438370 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10438370 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10438370 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10438370 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10438370 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10438370 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10438370 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10438370 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10438370 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10438370 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10438370 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10438370 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:10438370 | pubmed:issn | 0022-1899 | lld:pubmed |
| pubmed-article:10438370 | pubmed:author | pubmed-author:CHOT STS | lld:pubmed |
| pubmed-article:10438370 | pubmed:author | pubmed-author:KolbKK | lld:pubmed |
| pubmed-article:10438370 | pubmed:author | pubmed-author:DanKK | lld:pubmed |
| pubmed-article:10438370 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10438370 | pubmed:volume | 180 | lld:pubmed |
| pubmed-article:10438370 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10438370 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10438370 | pubmed:pagination | 811-20 | lld:pubmed |
| pubmed-article:10438370 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:10438370 | pubmed:meshHeading | pubmed-meshheading:10438370... | lld:pubmed |
| pubmed-article:10438370 | pubmed:meshHeading | pubmed-meshheading:10438370... | lld:pubmed |
| pubmed-article:10438370 | pubmed:meshHeading | pubmed-meshheading:10438370... | lld:pubmed |
| pubmed-article:10438370 | pubmed:meshHeading | pubmed-meshheading:10438370... | lld:pubmed |
| pubmed-article:10438370 | pubmed:meshHeading | pubmed-meshheading:10438370... | lld:pubmed |
| pubmed-article:10438370 | pubmed:meshHeading | pubmed-meshheading:10438370... | lld:pubmed |
| pubmed-article:10438370 | pubmed:meshHeading | pubmed-meshheading:10438370... | lld:pubmed |
| pubmed-article:10438370 | pubmed:meshHeading | pubmed-meshheading:10438370... | lld:pubmed |
| pubmed-article:10438370 | pubmed:meshHeading | pubmed-meshheading:10438370... | lld:pubmed |
| pubmed-article:10438370 | pubmed:meshHeading | pubmed-meshheading:10438370... | lld:pubmed |
| pubmed-article:10438370 | pubmed:meshHeading | pubmed-meshheading:10438370... | lld:pubmed |
| pubmed-article:10438370 | pubmed:meshHeading | pubmed-meshheading:10438370... | lld:pubmed |
| pubmed-article:10438370 | pubmed:meshHeading | pubmed-meshheading:10438370... | lld:pubmed |
| pubmed-article:10438370 | pubmed:meshHeading | pubmed-meshheading:10438370... | lld:pubmed |
| pubmed-article:10438370 | pubmed:meshHeading | pubmed-meshheading:10438370... | lld:pubmed |
| pubmed-article:10438370 | pubmed:meshHeading | pubmed-meshheading:10438370... | lld:pubmed |
| pubmed-article:10438370 | pubmed:meshHeading | pubmed-meshheading:10438370... | lld:pubmed |
| pubmed-article:10438370 | pubmed:meshHeading | pubmed-meshheading:10438370... | lld:pubmed |
| pubmed-article:10438370 | pubmed:meshHeading | pubmed-meshheading:10438370... | lld:pubmed |
| pubmed-article:10438370 | pubmed:meshHeading | pubmed-meshheading:10438370... | lld:pubmed |
| pubmed-article:10438370 | pubmed:meshHeading | pubmed-meshheading:10438370... | lld:pubmed |
| pubmed-article:10438370 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10438370 | pubmed:articleTitle | Synergistic effect of interferon-gamma and mannosylated liposome-incorporated doxorubicin in the therapy of experimental visceral leishmaniasis. | lld:pubmed |
| pubmed-article:10438370 | pubmed:affiliation | Department of Molecular Cell Biology, Indian Institute of Chemical Biology, Calcutta, India. | lld:pubmed |
| pubmed-article:10438370 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10438370 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10438370 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10438370 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10438370 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10438370 | lld:pubmed |
